Jeremy Sauer
Vice President, Strategy Callio Therapeutics
Jeremy is Vice President, Head of Strategy at Callio Therapeutics where he focuses on maximizing value of the company’s multi-payload ADC platform. He brings over a decade of cross-functional biopharma experience. Most recently, Jeremy held leadership roles at Seagen (acquired by Pfizer) spanning competitive intelligence, early-phase clinical development, business development, and R&D external innovation. Prior to Seagen, he was a market strategy consultant at ZS Associates and began his career as a manufacturing engineer at Procter & Gamble. Jeremy holds a PhD in Chemical Engineering from Rensselaer Polytechnic Institute.
Seminars
Tuesday 9th March 2027
Panel Discussion: Trailblazing Next Generation of ADC’s from XDC’s to Dual Payload Innovation to Develop Safer & More Efficacious ADC Drugs from Concept to Clinic Validation
5:00 pm
- Debating the optimal chemical and biological properties of next-generation payload and linker combinations
- Exploring the novelty of dual-payload ADCs and their potential to overcome resistance mechanisms associated with traditional ADCs
- Assessing the potential of novel ‘XDC’ candidates to expand therapeutic applications and unlock untapped opportunities within an increasingly crowded ADC landscape
